An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma

Trial Profile

An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 01 Dec 2015 Results published in the Annals of Hematology
    • 28 May 2014 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
    • 02 Jul 2013 Planned end date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top